Have a personal or library account? Click to login
Oxidative and apoptotic effects of fluoxetine and its metabolite norfluoxetine in Daphnia magna Cover

Oxidative and apoptotic effects of fluoxetine and its metabolite norfluoxetine in Daphnia magna

Open Access
|Oct 2020

Figures & Tables

Figure 1

Chronic effects of fluoxetine, norfluoxetine, and their combinations at environmental or 10-fold environmental concentrations on mitochondrial membrane potential in Daphnia magna (200 μm)
Chronic effects of fluoxetine, norfluoxetine, and their combinations at environmental or 10-fold environmental concentrations on mitochondrial membrane potential in Daphnia magna (200 μm)

Figure 2

Effects of fluoxetine, norfluoxetine, and their combinations at subacute, 100-fold environmental concentrations on mitochondrial membrane potential in Daphnia magna (200 μm)
Effects of fluoxetine, norfluoxetine, and their combinations at subacute, 100-fold environmental concentrations on mitochondrial membrane potential in Daphnia magna (200 μm)

Figure 3

Chronic effects of fluoxetine, norfluoxetine, and their combinations at environmental or 10-fold environmental concentrations on cytochrome c and ERK 1/2 protein levels in Daphnia magna. A – control; B– fluoxetine; C– norfluoxetine; D– fluoxetine+norfluoxetine; E – 10 x fluoxetine; F – 10 x norfluoxetine; G– 10 x fluoxetine+10 x norfluoxetine
Chronic effects of fluoxetine, norfluoxetine, and their combinations at environmental or 10-fold environmental concentrations on cytochrome c and ERK 1/2 protein levels in Daphnia magna. A – control; B– fluoxetine; C– norfluoxetine; D– fluoxetine+norfluoxetine; E – 10 x fluoxetine; F – 10 x norfluoxetine; G– 10 x fluoxetine+10 x norfluoxetine

Figure 4

Subacute effects of fluoxetine, norfluoxetine, and their combinations at 100-fold environmental concentrations on cytochrome c and ERK1/2 protein levels in Daphnia magna. A – control; B – 100 x fluoxetine; C – 100 x norfluoxetine; D – 100 x fluoxetine+100 x norfluoxetine
Subacute effects of fluoxetine, norfluoxetine, and their combinations at 100-fold environmental concentrations on cytochrome c and ERK1/2 protein levels in Daphnia magna. A – control; B – 100 x fluoxetine; C – 100 x norfluoxetine; D – 100 x fluoxetine+100 x norfluoxetine

Effects of fluoxetine (Flx), norfluoxetine (NorFlx), and their combinations on GPx, ChE, TBARS, and total protein levels in Daphnia magna

GPx (μmol/min/mg protein)ChE (μmol/min/mg protein)TBARS (nmol/mg protein)Total proteins (mg/mL)
Chronic
Control0.047±0.010a0.010±0.003ab8.169±2.892a1.143±0.271a
Flx0.048±0.002a0.012±0.001bc8.413±0.999a0.972±0.038a
NorFlx0.051±0.004a0.014±0.001c11.670±1.347ab0.996±0.032a
Flx+NorFlx0.056±0.010ac0.012±0.002bc8.750±1.106a0.948±0.037a
10 x Flx0.086±0.003b0.014±0.001c16.354±3.315b0.909±0.028a
10 x NorFlx0.062±0.010c0.010±0.001ab21.840±6.003c0.966±0.125a
10 x Flx+10 x NorFlx0.050±0.005a0.007±0.002a15.600±3.283b1.029±0.098a
Subacute*
Control0.063±0.005a0.016±0.003a10.635±3.731a0.681±0.107a
100 x Flx0.175±0.071bc0.058±0.020b67.963±32.735b0.365±0.048b
100 x NorFlx0.273±0.221b0.053±0.009b24.030±7.179c0.278±0.071b
100 x Flx+100 x NorFlx0.129±0.042c0.054±0.012b35.388±15.764bc0.297±0.069b

Chronic effects of fluoxetine, norfluoxetine, and their combinations at environmental or 10-fold environmental concentrations on brood production of D_ magna

1st generation offspring2nd generation offspring3rd generation offspring4th generation offspring5th generation offspringAverage
Control76.8±13.6a50.1±16.5ac44.1±16.4a73.9±15.3a84.8±32.3ac65.9±25.1a
Flx79.8±24.4ac46.2±5.7a62.7±18.1b78.7±32.1a81.3±29.7a69.7±26.9a
NorFlx143.3±44.7b69.5±25.4cdf140.7±51.8c135.6±64.2bc62.2±22.8cd110.3±56.6b
Flx+NorFlx126.3±29.9b94.3±43.4bd144.3±29.5c135.3±68.1b45.4±9.3b109.1±53.7b
10 x Flx129.5±59.0bd53.5±29.2aeg60.6±9.3b84.9±58.6ac41.8±17.4bd74.1±48.0ac
10 x NorFlx70.6±21.9a42.3±26.8e57.7±29.9ab52.7±33.2a67.6±27.6c58.2±29.1c
10 10 x x Flx NorFlx +98.6±31.8cd64.4±20.0fg56.8±8.9b60.6±48.5a42.3±15.5b64.5±33.4ac

Confirmation of water concentrations of fluoxetine (Flx) and norfluoxetine (NorFlx) after serial dilution

Concentrations0.091 μg/L0.91 μg/L9.10 μg/L0.011 μg/L0.11 μg/L1.10 μg/L
Flx0.090±0.0071.18±0.069.39±0.05---
NorFlx---0.010±0.0000.15±0.011.14±0.01

Chronic effects of fluoxetine (Fix), norfluoxetine (NorFlx), and their combinations at environmental or 10-fold environmental concentrations on carapace length, maximum carapace width, and caudal spine length in less than 24 h-old D_ magna offspring bom in experimental beakers

Carapace length (pm)Max. carapace width (pm)Caudal spine length (pm)Carapace length (pm)Max. carapace width (pm)Caudal spine length (pm)Carapace length (pm)Max. carapace width (pm)Caudal spine length (pm)
1st generation offspring2nd generation offspring3rd generation offspring
Control777.6±50.4430.0±41.0403.2±30.4880.9±85.9a473.7±86.9acd415.3±31.5847.0±46.1a490.6±52.8ad411.5±42.8a
Flx773.0±37.3414.5±43.1385.2±26.4827.8±76.1b437.5±62.9c400.6±33.1806.9±45.7b475.6±53.6ac371.2±42.0b
NorFlx748.5±30.4408.5±38.9354.0±34.6842.3±72.5b448.5±66.1ac403.5±28.6838.7±41.8a475.0±38.9ac378.1±44.4bc
Flx+NorFlx774.2±33.9420.9±47.8367.0±29.3857.3±56.1a466.0±55.1ad397.4±32.3812.4±45.2b469.2±45.4bc369.7±39.9b
10 x Flx742.6±32.7400.9±45.8345.1±25.9874.1±107.5ab496.4±97.7de406.1±43.0906.2±80.9c524.4±70.2e397.3±40.2ac
10 x NorFlx764.2±34.6407.6±36.9358.8±26.2893.8±101.5ac521.6±78.7be401.4±41.7857.9±69.4a492.8±68.0abf379.9±41.5bc
10 x Flx+10 x NorFlx733.7±34.1388.5±43.2349.4±41.9925.6±102.1c544.5±81.9b408.0±53.6915.7±105.3c524.0±90.6def380.3±56.7bc
4th generation offspring5th generation offspringAverage
Control887.6±22.5a483.0±31.2a392.0±31.3ae899.7±64.5a497.7±49.2a385.8±30.3ac865.0±70.3a478.3±59.6a401.0±35.4a
Flx842.9±27.4bd456.7±33.7bc414.1±32.4b783.7±58.2b446.4±35.1b363.0±51.7a805.9±58.5b444.5±50.0b386.8±42.6b
NorFlx852.2±55.1bc449.7±52.4b372.0±28.7cd890.9±100.1c503.9±71.5af389.8±49.7cb831.1±78.7c455.8±62.4bd378.8±41.5c
Flx+NorFlx878.8±56.8a473.4±60.4ac367.7±31.6d891.2±94.0ac532.3±63.7c395.5±35.5cb836.7±74.8c468.3±65.8cef378.7±36.0c
10 x Flx845.3±47.1bd454.4±37.5b395.9±29.0a836.9±35.9d462.1±30.5ed394.0±25.7b841.0±86.0c467.6±73.6deg387.9±39.6bd
10 x NorFlx855.9±22.2c480.4±24.8a394.0±41.5a838.4±98.5e476.5±69.7def386.7±44.6ab837.8±84.4c472.2±71.4afg382.3±41.5cd
10 x Flx+10 x NorFlx833.0±42.3d465.9±25.9c381.0±23.8ce833.0±88.7de470.2±61.0be381.0±45.3ab849.9±105.7c480.2±84.1afg381.0±48.9cd
DOI: https://doi.org/10.2478/aiht-2020-71-3473 | Journal eISSN: 1848-6312 | Journal ISSN: 0004-1254
Language: English, Croatian, Slovenian
Page range: 211 - 222
Submitted on: Jul 1, 2020
Accepted on: Sep 1, 2020
Published on: Oct 6, 2020
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 Sevgi Başalan Över, Celal Güven, Eylem Taskin, Yusuf Sevgiler, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.